Shareholder Alert: Ademi LLP investigates whether Vivakor, Inc. has obtained a Fair Price in its transaction with Empire Diversified Energy
Shareholder Alert: Ademi LLP investigates whether Vivakor, Inc. has obtained a Fair Price in its transaction with Empire Diversified Energy
PR Newswire
MILWAUKEE, March 5, 2024
MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Vivakor (NASDAQ: VIVK) for possible breaches of fiduciary duty and other violations of law in its transaction with Empire Diversified Energy.
Click here to learn how to join the https://www.ademilaw.com/case/vivakor-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Vivakor would acquire all the outstanding shares of Empire common and preferred stock, on an as-converted basis, for net consideration of 67,200,000 shares of Vivakor common stock, resulting in Empire becoming a wholly-owned subsidiary of Vivakor upon the closing.
We are investigating the conduct of Vivakor's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Vivakor common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/vivakor-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth